Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | DRD1 | P21728 | 7/20 | 0.46 |
| ▸ | DRD5 | P21918 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886570 | 0.81 | DRD2 (0.42) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL19121066 | 0.76 | DRD2 (0.55) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL17662597 | 0.76 | DRD2 (0.55) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL10465500 | 0.75 | HTR1A (0.40) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL162104 | 0.74 | DRD2 (0.48) | DRD2DRD1DRD5DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL11458075 | 0.74 | DRD2 (0.54) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL28749727 | 0.70 | DRD2 (0.41) | DRD2DRD3HTR2AHTR2C | |
| SCHEMBL28922653 | 0.69 | HTR2C (0.47) | HTR2AHTR2C | |
| SCHEMBL164206 | 0.69 | DRD1 (0.85) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL29391320 | 0.69 | DRD1 (0.85) | DRD2DRD1DRD5DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | DRD2 169/4885DRD1 144/4885DRD5 177/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | DRD2 184/4885DRD1 154/4885DRD5 195/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | DRD2 171/4885DRD1 156/4885DRD5 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.